| Literature DB >> 35497972 |
Dmitry A Makarov1, Olga E Ivanova2, Anastasia V Pomazkova2, Maria A Egoreva2, Olga V Prasolova2, Sergey V Lenev2, Maria A Gergel3, Nataliya K Bukova4, Sergey Yu Karabanov5.
Abstract
Background and Aim: Although Enterococcus faecalis and Enterococcus faecium are common members of human and animal gut microbiota, their resistance to different antimicrobials makes them important pathogens. Multidrug-resistant enterococci often contaminate foods of animal origin at slaughterhouses. The World Health Organization and the World Organization for Animal Health recommend including animal-derived enterococci in antimicrobial resistance (AMR) monitoring programs. This study aimed to fill a literature gap by determining the current AMR prevalence of E. faecalis and E. faecium from different food-producing animals in Russia. Materials andEntities:
Keywords: Enterococcus faecalis; Enterococcus faecium; animals; antimicrobial resistance; enterococci; livestock
Year: 2022 PMID: 35497972 PMCID: PMC9047118 DOI: 10.14202/vetworld.2022.611-621
Source DB: PubMed Journal: Vet World ISSN: 0972-8988
The number of samples depending of farm, sample type, and age group.
| Animal species and age groups | Number of samples, Sample type, (Age group), Farm №. | |
|---|---|---|
| Chicken ( |
| 38CS (Br) - Farm №5 |
| 2FE (Br) - Farm №6 | ||
| 18FE (Ha) - Farm №7 | ||
| 24CS (Br) - Farm №8 | ||
| 4FE (Br) - Farm №9 | ||
| 5CS (Br) - Farm №10 | ||
| 7FE (Br) - Farm №12 | ||
| 13CS (Br), 15FE (Br) - Farm №18 | ||
| 20CS (Br) - Farm №23 | ||
|
| 5CS (Br) - Farm №5 | |
| 5CS (Br) - Farm №8 | ||
| 4FE (Br) - Farm №9 | ||
| 6FE (Br) - Farm №12 6CS (Br) - Farm №13 | ||
| 18CS (Br) - Farm №18 | ||
| Turkey ( |
| 11LI (Ad), 3 CS (Ad) - Farm №3 |
| 20CS (Tp) - Farm №4 | ||
| Duck ( |
| 9CS, 7FE, 4 LI - Farm №15 |
| 7FE, 4LI - Farm №20 | ||
| Cattle ( |
| 9FE, 7LI- Farm №2 |
| 2LI - Farm №16 | ||
| 5VS - Farm №19 | ||
| 6FE, 2LI - Farm №24 | ||
| 3LI - Farm №25 | ||
| 9FE, 1VS- Farm №27 | ||
| 4LI, 3FE – Farm № 30 | ||
|
| 1FE, 1LI - Farm №16 | |
| 21FE- Farm №17 | ||
| 10VS, 5FE- Farm №19 | ||
| 6FE, 5LI - Farm №24 | ||
| 8FE, 2LI - Farm №25 | ||
| 7FE, 7VS- Farm №27 | ||
| 15FE, 10VS – Farm № 28 | ||
| 4FD, 3FE, 3LI – Farm № 30 | ||
| Pig ( |
| 5FE (2 Pi, 3 Fs), 7LI (4Ad, 3Pi) - Farm №1 |
| 25FE (13 Fs, 6 Pi, 6 Yo) - Farm №11 | ||
| 10 FE (8Pi, 2Fs), 2LI (Ad) - Farm №26 | ||
| Sheep ( |
|
Totally 487 isolates (277 of Enterococcus faecalis and 210 of Enterococcus faecium), Sample types: CS=Carcass swab, FE=Feces, LI=Litter, VS=Vagina swab. Farm № 1 is located in Altai Krai, №2=In Bashkortostan, №3-9=In Belgorod oblast, №10-11=In Chelyabinsk oblast, № 12-14=In Dagestan, №15=In Kaliningrad oblast, №16-17=In Kaluga oblast, №18-19=In Novosibirsk oblast, №20-22=In Orenburg oblast, №23=In Penza oblast, №24-25=In Ryazan oblast, №26=In Sverdlovsk oblast, №27=In Tver oblast, №28=In Voronezh oblast, №29-30=In Yaroslavl oblast
Resistance patterns of enterococci isolates, depending on the animal species (interpretation against ECOFFs).
| Antimicrobial |
|
| ||||
|---|---|---|---|---|---|---|
|
|
| |||||
| Number of isolates tested | Resistant isolates, % | 95% Confidence interval | Number of isolates tested | Resistant isolates, % | 95% Confidence interval | |
|
|
| |||||
| AMP | 51 | 0 | 0-7 | 104 | 1 | 0.2-5.3 |
| BAC | 34 | 100 | 89.9-100 | 27 | 96.3 | 81.7-99.3 |
| CHL | 51 | 9.8 | 4.3-21 | 104 | 0 | 0-3.6 |
| CIP | 51 | 0 | 0-7 | 104 | 1 | 0.2-5.3 |
| ERY | 51 | 13.7 | 6.8-25.7 | 104 | 35.6 | 27-45.1 |
| GEN | 51 | 0 | 0-7 | 104 | 0 | 0-3.6 |
| STR | 51 | 2 | 0.4-10.3 | 104 | 0 | 0-3.6 |
| TET | 51 | 15.7 | 8.2-28 | 104 | 7.7 | 4-14.5 |
| VAN | 51 | 0 | 0-7 | 104 | 0 | 0-3.6 |
| VIR | 34 | 32.4 | 19.1-49.2 | 27 | 100 | 87.5-100 |
|
|
| |||||
| AMP | 146 | 0 | 0-2.6 | 41 | 14.6 | 6.9-28.4 |
| CHL | 146 | 21.9 | 16-29.3 | 41 | 0 | 0-8.6 |
| CIP | 146 | 24.7 | 18.4-32.2 | 41 | 39 | 25.7-54.3 |
| ERY | 146 | 60.3 | 52.2-67.9 | 41 | 61 | 45.7-74.3 |
| GEN | 146 | 1.4 | 0.4-4.9 | 41 | 19.5 | 10.2-34 |
| STR | 146 | 3.4 | 1.5-7.8 | 41 | 7.3 | 2.5-19.4 |
| TET | 146 | 95.2 | 90.4-97.7 | 41 | 48.8 | 34.3-63.5 |
| VAN | 146 | 0 | 0-2.6 | 41 | 0 | 0-8.6 |
|
|
| |||||
| AMP | 31 | 0 | 0-11 | 34 | 5.9 | 1.6-19.1 |
| CHL | 31 | 3.2 | 0.6-16.2 | 34 | 0 | 0-10.2 |
| CIP | 31 | 3.2 | 0.6-16.2 | 34 | 100 | 89.9-100 |
| ERY | 31 | 9.7 | 3.4-24.9 | 34 | 100 | 89.9-100 |
| GEN | 31 | 3.2 | 0.6-16.2 | 34 | 94.1 | 80.9-98.4 |
| STR | 31 | 3.2 | 0.6-16.2 | 34 | 76.5 | 60-87.6 |
| TET | 31 | 45.2 | 29.2-62.2 | 34 | 100 | 89.9-100 |
| VAN | 31 | 0 | 0-11 | 34 | 0 | 0-10.2 |
|
|
| |||||
| AMP | 49 | 0 | 0-7.3 | 31 | 0 | 0-11 |
| BAC | 24 | 87.5 | 69-95.7 | 6 | 100 | 61-100 |
| CHL | 49 | 22.5 | 13-35.9 | 31 | 0 | 0-11 |
| CIP | 49 | 20.4 | 11.5-33.6 | 31 | 0 | 0-11 |
| ERY | 49 | 87.8 | 75.8-94.3 | 31 | 16.1 | 7.1-32.6 |
| GEN | 49 | 53.1 | 39.4-66.3 | 31 | 0 | 0-11 |
| STR | 49 | 30.6 | 19.5-44.5 | 31 | 0 | 0-11 |
| TET | 49 | 100 | 92.7-100 | 31 | 19.4 | 9.2-36.3 |
| VAN | 49 | 0 | 0-7.3 | 31 | 0 | 0-11 |
| VIR | 24 | 100 | 86.2-100 | 6 | 100 | 61-100 |
AMP = Ampicillin, BAC = Bacitracin, CHL = Chloramphenicol, CIP = Ciprofloxacin, ERY = Eythromycin, GEN = Gentamicin, RIF = Rifampicin, STR = Streptomycin, TET = Tetracycline, TRI = Trimetohoprim, TRI-SUL = Trimethoprim-Sulfamethoxazole, VAN = Vancomycin, VIR = Virginiamycin
Resistance patterns of enterococci isolates depending on the animal species (interpretation against EUCAST 2021).
| Antimicrobial |
|
| ||
|---|---|---|---|---|
|
|
| |||
| Resistant isolates, % | 95% Confidence interval | Resistant isolates, % | 95% Confidence interval | |
|
|
| |||
| AMP | 0 | 0-7 | 1 | 0.2-5.3 |
| CIP | 0 | 0-7 | 1 | 0.2-5.3 |
| GEN | 0 | 0-7 | 0 | 0-3.6 |
| STR | 2 | 0.4-10.3 | 0 | 0-3.6 |
| TRI | 11.8 | 5.5-23.4 | 14.4 | 8.9-22.4 |
| TRI-SUL | 11.8 | 5.5-23.4 | 0 | 0-3.6 |
| VAN | 0 | 0-7 | 0 | 0-3.6 |
|
|
| |||
| AMP | 0 | 0-2.6 | 14.6 | 6.9-28.4 |
| CIP | 24.7 | 18.4-32.2 | 39 | 25.7-54.3 |
| GEN | 1.4 | 0.4-4.9 | 4.9 | 1.4-16.1 |
| STR | 3.4 | 1.5-7.8 | 4.9 | 1.4-16.1 |
| TRI | 20.6 | 14.8-27.8 | 34.2 | 21.6-49.5 |
| TRI-SUL | 32.9 | 25.8-40.9 | 36.6 | 23.6-51.9 |
| VAN | 0 | 0-2.6 | 0 | 0-8.6 |
|
|
| |||
| AMP | 0 | 0-11 | 5.9 | 1.6-19.1 |
| CIP | 3.2 | 0.6-16.2 | 100 | 89.9-100 |
| GEN | 3.2 | 0.6-16.2 | 94.1 | 80.9-98.4 |
| STR | 3.2 | 0.6-16.2 | 52.9 | 36.7-68.6 |
| TRI | 3.2 | 0.6-16.2 | 52.9 | 36.7-68.6 |
| TRI-SUL | 3.2 | 0.6-16.2 | 52.9 | 36.7-68.6 |
| VAN | 0 | 0-11 | 0 | 0-10.2 |
|
|
| |||
| AMP | 0 | 0-7.3 | 0 | 0-11 |
| CIP | 20.4 | 11.5-33.6 | 3.2 | 0.6-16.2 |
| GEN | 51 | 37.5-64.4 | 0 | 0-11 |
| STR | 30.6 | 19.5-44.5 | 0 | 0-11 |
| TRI | 55.1 | 41.3-68.2 | 0 | 0-11 |
| TRI-SUL | 53.1 | 39.4-66.3 | 0 | 0-11 |
| VAN | 0 | 0-7.3 | 0 | 0-11 |
AMP=Ampicillin, BAC=Bacitracin, CHL=Chloramphenicol, CIP=Ciprofloxacin, ERY=erythromycin, GEN=gentamicin, RIF=Rifampicin, STR=Streptomycin, TET=Tetracycline, TRI=Trimetohoprim, TRI-SUL=Trimethoprim-Sulfamethoxazole, VAN=Vancomycin, VIR=Virginiamycin
Resistance patterns of enterococci isolates depending on the animal species (interpretation against CLSI 2021).
| Antimicrobial |
|
| ||
|---|---|---|---|---|
|
|
| |||
| Resistant isolates, % | 95% Confidence interval | Resistant isolates, % | 95% Confidence interval | |
|
|
| |||
| AMP | 0 | 0-7 | 1 | 0.2-5.3 |
| CHL | 9.8 | 4.3-21 | 1 | 0.2-5.3 |
| CIP | 2 | 0.4-10.3 | 20.2 | 13.6-28.9 |
| ERY | 13.7 | 6.8-25.7 | 35.6 | 27-45.1 |
| GEN | 0 | 0-7 | 0 | 0-3.6 |
| RIF | 84.3 | 72-91.8 | 70.2 | 60.8-78.1 |
| STR | 2 | 0.4-10.3 | 0 | 0-3.6 |
| TET | 15.7 | 8.2-28 | 7.7 | 4-14.5 |
| VAN | 0 | 0-7 | 0 | 0-3.6 |
|
|
| |||
| AMP | 0 | 0-2.6 | 14.6 | 6.9-28.4 |
| CHL | 21.9 | 16-29.3 | 4.9 | 1.4-16.1 |
| CIP | 24.7 | 18.4-32.2 | 75.6 | 60.7-86.2 |
| ERY | 60.3 | 52.2-67.9 | 61 | 45.7-74.3 |
| GEN | 0 | 0-2.6 | 0 | 0-8.6 |
| RIF | 48 | 40-56 | 43.9 | 29.9-59 |
| STR | 3.4 | 1.5-7.8 | 4.9 | 1.4-16.1 |
| TET | 95.2 | 90.4-97.7 | 48.8 | 34.3-63.5 |
| VAN | 0 | 0-2.6 | 0 | 0-8.6 |
|
|
| |||
| AMP | 0 | 0-11 | 5 | 1.4-16.5 |
| CHL | 6.5 | 1.8-20.7 | 50 | 35.2-64.8 |
| CIP | 6.5 | 1.8-20.7 | 100 | 91.2-100 |
| ERY | 9.7 | 3.4-24.9 | 100 | 91.2-100 |
| GEN | 0 | 0-11 | 0 | 0-8.8 |
| RIF | 83.9 | 67.4-92.9 | 50 | 35.2-64.8 |
| STR | 3.2 | 0.6-16.2 | 45 | 30.7-60.2 |
| TET | 45.2 | 29.2-62.2 | 100 | 91.2-100 |
| VAN | 0 | 0-11 | 0 | 0-8.8 |
|
|
| |||
| AMP | 0 | 0-7.3 | 0 | 0-11 |
| CHL | 22.5 | 13-35.9 | 0 | 0-11 |
| CIP | 22.5 | 13-35.9 | 32.3 | 18.6-49.9 |
| ERY | 87.8 | 75.8-94.3 | 16.1 | 7.1-32.6 |
| GEN | 0 | 0-7.3 | 0 | 0-11 |
| RIF | 65.3 | 51.3-77.1 | 77.4 | 60.2-88.6 |
| STR | 30.6 | 19.5-44.5 | 0 | 0-11 |
| TET | 100 | 92.7-100 | 19.4 | 9.2-36.3 |
| VAN | 0 | 0-7.3 | 0 | 0-11 |
AMP=Ampicillin, BAC=Bacitracin, CHL=Chloramphenicol, CIP=Ciprofloxacin, ERY=erythromycin, GEN=gentamicin, RIF=Rifampicin, STR=Streptomycin, TET=Tetracycline, TRI=Trimetohoprim, TRI-SUL=Trimethoprim-Sulfamethoxazole, VAN=Vancomycin, VIR=Virginiamycin
Figure-1Trimethoprim-sulfamethoxazole minimum inhibitory concentration distribution among Enterococcus faecalis isolates. Green columns – percent of susceptible isolates, red – resistant (EUCAST 2021 breakpoints), N – number of isolates.
Figure-2Trimethoprim-sulfamethoxazole minimum inhibitory concentration distribution among Enterococcus faecium isolates. Green columns – percent of susceptible isolates, red – resistant (EUCAST 2021 breakpoints), N – number of isolates.
Figure-3Rifampicin minimum inhibitory concentration distribution among Enterococcus faecalis isolates. Green columns – percent of susceptible isolates, yellow – intermediate resistant, red – resistant (CLSI 2021 breakpoints), N – number of isolates.
Figure-4Rifampicin minimum inhibitory concentration distribution among Enterococcus faecium isolates. Green columns – percent of susceptible isolates, yellow – intermediate resistant, red – resistant (CLSI 2021 breakpoints), N – number of isolates.
Figure-5Patterns of simultaneous resistance to different classes of antimicrobials. Sus (S+I) means the percent of isolates susceptible to all antimicrobials tested (susceptible + intermediate categories according to CLSI 2021). Res 1 means the percent of isolates resistant to at least 1 antimicrobial, Res 2 – to 2 antimicrobials, etc.